MarketWatch (press release) Interviewed thought leaders are optimistic that the CRd regimen-- carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone --will show advantages over sales-leading ... and more »
7thSpace Interactive (press release) Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe ...
Nursing Times Researchers found that vitamin D reduced the levels of IL-17A produced by cells from people with asthma. This included cells from people who had previously failed to respond to the treatment of choice for severe asthma – oral corticosteroids – often ... and more »
MarketWatch (press release) Interviewed thought leaders are optimistic that the CRd regimen-- carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone --will show advantages over sales-leading ... and more »
EON: Enhanced Online News (press release) BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly ...
7thSpace Interactive (press release) Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe ...
